Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Cystic Fibrosis

• A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
• A Phase 1, First-in-human Study of VX-828
• SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
• A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
• Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
• An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
• A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
• Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
• Semaglutide in CFRD
• Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
• Pilot Study to Assess Safety and Efficacy of an Enteric Microgranule Formulation of Adrulipase in Patients With Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis (CF).
• Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects
• Estrogen Patches for Adolescent and Young Adult Women With Cystic Fibrosis
• A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF)
• Study to Determine the Efficacy&Safety of ARV-1801/ACG-701 for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
• Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
• Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
• A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor
• A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
• BEGIN Novel ImagiNG Biomarkers
• A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
• Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
• Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
• Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
• Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
• Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF
• Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
• Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
• Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
• A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
• Phase II Study of a Nebulised Nitric Oxide Generating Solution in Patients With Cystic Fibrosis
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Res
• Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
• Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
• A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Subjects With Cystic Fibrosis (CF)
• A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection
• A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis
• GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
• CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
• Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
• Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
• A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
• Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
• Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF
• A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Subjects 6 Years and Older and F/MF Genotypes
• Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
• Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes
• Effects of Metformin on Airway Ion Channel Dysfunction in Cystic Fibrosis-related Diabetes
• Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
• Pharmacokinetics of Omadacycline in Cystic Fibrosis
• Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis
• Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis
• The Role of Vitamin D3 in Pediatric Bronchiectasis Severity
• Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes
• OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
• Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
• A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
• A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
• Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer
• Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs
• IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
• Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
• Hyperpolarized Imaging for New Treatments
• A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
• Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
• Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
• Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older
• Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients
• Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis
• A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
• A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
• Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis
• A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
• A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
• A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
• Sildenafil Exercise: Role of PDE5 Inhibition
• A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
• Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
• A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
• Functional Respiratory Imaging and Orkambi in CF
• A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
• A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocr
• Markers of Osteoporosis in Cystic Fibrosis
• A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
• A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
• Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
• Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis
• Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.
• The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
• A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis
• Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis
• Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
• A DDI Study of FDL169 and FDL176 in Healthy Subjects
• Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF
• OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
• Pilot E2 for Hypogonadal Women With CFBD
• A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
• SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
• Effects of AD on VI in Patients With CF
• A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
• Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
• Intravenous Iron in Adults With Cystic Fibrosis
• A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
• Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
• Project 2 Airway Potential Hydrogen (pH) in Asthma
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
• Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
• Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis
• Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.
• Personalized Theratyping Trial
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
• PPIs and Fat Absorption in CF and EPI
• A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation
• A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
• A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
• A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
• CF Bronchodilation
• A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects
• Trikafta in Cystic Fibrosis Patients
• Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules
• Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
• 19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation
• STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
• 19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis
• DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis
• Comparison of 129Xe MRI With 19F MRI in CF Lung Disease
• GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis
• A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
• Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
• Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis
• A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
• Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
• An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects
• Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis
• Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
• Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients
• Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis
• A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis
• A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
• Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults
• Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy
• PTC Study to Evaluate Ataluren in Combination With Ivacaftor
• Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
• Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis
• An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
• A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
• A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
• Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection
• Inhaled Nitric Oxide for Patients With MABSC
• Losartan and Inflammation in Cystic Fibrosis
• AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
• A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
• Telavancin Pharmacokinetics in Cystic Fibrosis Patients
• SynRinse Irrigation Pilot (SIP) Trial
• A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)
• Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
• A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
• Clearance of 25-hydroxyvitamin D in Cystic Fibrosis
• A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
• Airway Alkalinization and Nasal Colonization
• Prednisone in Cystic Fibrosis Pulmonary Exacerbations
• A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
• Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis
• Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
• A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
• A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
• RESULT: Reliable, Emergent Solution Using Liprotamase Treatment
• A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis
• Effect of Azithromycin on Fatty Acids in CF
• A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
• The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis
• A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
• BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects
• Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
• Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
• A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
• A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
• Saline Hypertonic in Preschoolers + CT
• A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
• Multilevel Models of Therapeutic Response in the Lungs
• An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
• MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)
• A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule
• A Study of RPL554 in Patients With Cystic Fibrosis
• IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
• Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis
• Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients
• A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
• The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia
• Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI
• LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
• EASY: Extended Access to Sollpura Over Years
• A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation
• ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
• Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
• Standardized Treatment of Pulmonary Exacerbations II
• Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
• Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
• Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
• Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
• A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
• Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease
• SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
• Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
• A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
• Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
• Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®
• A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients
• Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis
• A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
• Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)
• Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
• Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)
• Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)
• Pharmacokinetics of FDL169 in Healthy Female Subjects
• To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
• Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)
• Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del
• Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
• Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis
• Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers
• Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients
• Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
• Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation
• Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
• Special Drug Use Investigation of Ciproxan Injection in Pediatrics
• Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
• Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
• Evaluation of Nebulization and Positive Expiratory Pressure Combination
• Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
• Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
• A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
• A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
• A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis
• Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
• The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients
• Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis
• Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
• Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
• Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
• A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection
• Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
• Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
• Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
• EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
• Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
• Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Respons
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFT
• Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
• Saline Hypertonic in Preschoolers
• Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
• FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers
• A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
• Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)
• Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
• Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)
• (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?
• RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study
• Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium
• SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis
• A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index
• Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
• Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
• Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
• Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
• Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa
• DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis
• PK Study of N91115 in Cystic Fibrosis Patients
• Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex
• First Study of Oral Cysteamine in Cystic Fibrosis
• Redox Imbalance and the Development of Cystic Fibrosis Diabetes
• Evaluation of the Timing of the Nebulization Related to the Physiotherapy Session
• Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation
• Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
• Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
• Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients
• Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
• MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children
• A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis
• Cystic Fibrosis Related Diabetes
• Contraceptive Hormones and Women With Cystic Fibrosis
• Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis
• A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device
• Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
• A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
• A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
• Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
• Study of Ataluren (PTC124) in Cystic Fibrosis
• In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation
• Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
• Blood Flow and Vascular Function in Cystic Fibrosis
• OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
• Gender Disparity and Hormones in Cystic Fibrosis
• Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
• An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
• Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis
• A Study to Investigate Lung Deposition of Radiolabelled OligoG
• Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
• Investigating the Incretin Effect in Cystic Fibrosis
• Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis
• Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects
• Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
• Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients
• CPET in CF Patients With One G551D Mutation Taking VX770
• A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
• Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
• Phase 1, QT/QTC Interval Study in Healthy Subjects
• A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor
• Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
• Repeatability and Response Study of Absorptive Clearance Scans
• Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years
• Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
• Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis
• Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
• An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
• Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis
• Beta-cell Response to Incretin Hormones in Cystic Fibrosis
• Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
• Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
• Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
• Treatment of Low Bone Density in Cystic Fibrosis.
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
• A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
• Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
• Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
• A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
• Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis
• Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
• Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
• Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
• Imaging Lung Function Using Oxygen Enhanced MRI
• Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis
• A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
• Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
• Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
• Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
• Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation
• Zoledronic Acid in Cystic Fibrosis
• Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
• Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis
• Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
• A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
• Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
• Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.
• Repeated Application of Gene Therapy in CF Patients
• Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
• Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis
• Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
• ATCF (Azole Therapy in Cystic Fibrosis)
• A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
• Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
• Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis
• Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
• Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
• Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis
• A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis
• Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis
• Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
• Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis
• Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
• Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways
• Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis
• VX-770 Expanded Access Program
• Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis
• Aztreonam Lysine for Pseudomonas Infection Eradication Study
• Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis
• Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
• Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis
• Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
• Doxycycline Effects on Inflammation in Cystic Fibrosis
• Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
• Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
• Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
• Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo
• Hypertonic Saline and Mucociliary Clearance in Children
• Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
• Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
• Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
• Prevention of Bronchiectasis in Infants With Cystic Fibrosis
• Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
• Sitagliptin in Cystic Fibrosis-Related Diabetes
• Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients
• Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
• Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
• Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
• Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects
• Sildenafil Trial in Children and Young Adults With CF
• A Safety and Tolerability Study of Denufosol in 2-4 Year Olds
• MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
• Tiotropium Bromide in Cystic Fibrosis
• Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
• Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients
• Pulmozyme in Cystic Fibrosis With Sinusitis
• Study of VX-770 on Desipramine
• Cystic Fibrosis (CF) Exacerbation and Insulin Treatment
• Extension Study of Ataluren (PTC124) in Cystic Fibrosis
• Effects of Sildenafil on CFTR-dependent Ion Transport Activity
• PR-018: An Open-Label, Safety Extension of Study PR-011
• Rollover Study of VX-770 in Cystic Fibrosis Subjects
• Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer
• Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients
• A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
• Cystic Fibrosis - Insulin Deficiency, Early Action
• A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age
• Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis
• A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients
• Statins To Treat Adult Cystic Fibrosis
• Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa
• Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
• Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
• Second Open Label Extension to Bridging Study CTBM100C2303
• Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection
• Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
• Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis
• Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
• Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis
• A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
• Study of VX-770 and Rifampin in Healthy Male Subjects
• Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?
• Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
• A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
• The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function
• Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
• Open Label Extension to Bridging Study CTBM100C2303
• Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
• Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
• Prevention of Cystic Fibrosis Diabetes
• Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
• A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
• Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?
• Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
• Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects
• A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo
• Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
• Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
• 28 Day Repeat Dose in Cystic Fibrosis Patients
• A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
• Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
• Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
• Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)
• Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders
• RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum
• "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"
• Comparison of Antibiotics for Pseudomonas in Early CF
• Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis
• NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients
• Study of Ataluren (PTC124™) in Cystic Fibrosis
• Growth Hormone Therapy for Wasting in Cystic Fibrosis
• Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
• Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
• Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients
• Single Dose of pGM169/GL67A in CF Patients
• An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
• Phase II Study of Digitoxin to Treat Cystic Fibrosis
• Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
• Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
• Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization
• Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
• A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
• Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
• Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis
• A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease
• Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
• Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency
• Miglustat in Cystic Fibrosis
• Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
• Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis
• Effect of Pioglitazone on Inflammation in Cystic Fibrosis
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
• Infant Study of Inhaled Saline in Cystic Fibrosis
• Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis
• Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways
• Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)
• Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay
• Choline Nutrition in Children With Cystic Fibrosis (CF)
• A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
• Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
• Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis
• Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients
• Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis
• A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
• Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
• Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
• Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
• The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis
• Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin
• Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
• Long Term Administration of Inhaled Mannitol in Cystic Fibrosis
• Self-dispersing Liquids as Aerosol Drug Carriers
• Pharmacokinetics of Linezolid in Children With Cystic Fibrosis
• Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
• Repeat Dose Study in Male Healthy Volunteer Smokers
• SD Cystic Fibrosis Study
• Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)
• Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
• IGF-1 Therapy in Patients With Cystic Fibrosis
• Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
• The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
• Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone
• Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis
• Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis
• Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
• Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
• Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
• Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
• Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
• Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
• Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis
• Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients
• Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis
• Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients
• Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
• Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
• One Year Glargine Treatment in CFRD Children and Adolescents
• Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis
• A Study of Ataluren in Pediatric Participants With Cystic Fibrosis
• Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
• A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis
• Improving Vitamin D Status In Cystic Fibrosis
• Open-Label Phase III Long-Term Safety Trial of Liprotamase
• Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
• Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study
• A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
• Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
• Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa
• Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease
• Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study
• Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
• Scandinavian Cystic Fibrosis Azithromycin Study
• Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)
• The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
• Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study
• Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
• Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
• A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
• Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients
• Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease
• PTC124 for the Treatment of Cystic Fibrosis
• Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis
• A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
• Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease
• Hydroxychloroquine in Cystic Fibrosis
• Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
• Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex
• Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
• Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.
• Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis
• Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis
• Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
• The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis
• Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
• Growth Hormone Treatment Study in Children With Cystic Fibrosis
• Effect of Simvastatin on CF Airway Inflammation
• Mannitol Dose Response Study in Cystic Fibrosis
• Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain
• Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis
• PTC124 for Cystic Fibrosis
• Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
• Insulin Glargine Vs Standard Insulin Therapy
• Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis
• Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)
• Assessment of Inflammatory Mediators (AIM)
• Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis
• An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption
• Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis
• Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
• Effectiveness of Pulmozyme in Infants With Cystic Fibrosis
• The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation
• Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis
• Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
• Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
• A Study in Pediatric Patients With Cystic Fibrosis Lung Disease
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
• Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
• Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis
• International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
• Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)
• Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
• Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
• Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
• Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)
• A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis
• Diabetes Therapy to Improve BMI and Lung Function in CF
• Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients
• Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
• Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis
• Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
• A Study in Adult and Pediatric Patients With Cystic Fibrosis
• Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)
• Phase II Study of Growth Hormone in Children With Cystic Fibrosis
• Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis
• A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis
• Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis
• Growth Hormone Use in Cystic Fibrosis - a Multicenter Study
• A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis
• Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis
• Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis
• Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis
• Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis
• Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
• Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis
• Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis
• Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis
• Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease